Trial intelligence / Profile preview

Sedation regimens during percutaneous coronary intervention: midazolam-based combinations vs midazolam alone

IRCT20200825048515N81Phase 3Completed

Sponsor
Isfahan University of Medical Sciences
Start
Jul 2025
Modality
Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised trial of midazolam, propofol, ketamine and fentanyl in coronary arteriosclerosis (4 arms), sponsored by Isfahan University of Medical Sciences. Started Jul 2025; status: completed.

02

Drugs

midazolampropofolketaminefentanyl
03

Conditions

coronary arteriosclerosis

Beyond the preview

Go deeper on IRCT20200825048515N81.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20200825048515N81.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call